Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9612 posts found.

biogen_logo

Biogen reports on Tecfidera multiple sclerosis clinical trials

October 9, 2015 Research and Development

Biogen has presented data demonstrating the efficacy and safety of Tecfidera (dimethyl fumarate) across a broad range of people with …
News
sativex

Almirall presents new data on cannabinoid-based MS treatment

October 9, 2015 Research and Development Almirall, multiple sclerosis

Almirall has presented new clinical evidences of Sativex, the only medicine derived from cannabinoids to treat spasticity symptoms in MS, …
News
money_pills

Oncology groups and doctors fight for lower-priced cancer treatments

October 9, 2015 Medical Communications, Research and Development, Sales and Marketing

Oncology groups such as the American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network (NCCN) are working …
News
merckincweb2

Merck announces positive Elbasvir/Grazoprevir trial results

October 9, 2015 Research and Development

Merck has announced the publication of results from C-SURFER, the first Phase III clinical trial to investigate an all-oral, ribavirin-free …
News
astrazeneca_plaque

AstraZeneca’s Moventig now available through NHS

October 9, 2015 Medical Communications, Research and Development, Sales and Marketing AstraZeneca, moventig

AstraZeneca has announced that Moventig (naloxegol) has been made available for adult patients with opioid-induced constipation (OIC) in England and …
News
bronchial_thermoplasty

Taking on IFP, COPD and severe asthma: ERS 2015 roundup

October 9, 2015 Medical Communications, Research and Development

Leading pharmaceutical companies, physicians, healthcare professionals, scientists, respiratory experts, and of course the media, including Pharmafocus, gathered in Amsterdam at the …
Feature
Genentech logo

Positive late-stage results for Genentech’s ocrelizumab in different forms of MS

October 8, 2015 Research and Development ECTRIMS, Genentech, MS, Roche, multiple sclerosis, ocrelizumab

Roche’s biotech arm Genentech has presented ‘transformative’ data at an international multiple sclerosis conference on its investigational drug ocrelizumab. Ocrelizumab …
News
obesity

Innovative pipeline can transform obesity treatment, says GBI Research

October 8, 2015 Research and Development obesity

While the current obesity treatment market has a high level of unmet need, the therapeutic landscape could be transformed by …
News
troponin_blood_test

Simple blood test can accurately predict imminent heart attacks

October 8, 2015 Research and Development NHS, heart attack

A simple blood test which predicts whether a patient suffering chest pains will have a heart attack has the potential to save …
News
Gilenya

Novartis looks to new measure of Gilenya outcomes

October 8, 2015 Research and Development fingolimod, gilenya, multiple sclerosis, relapsing multiple sclerosis

Novartis says a new analysis from two Phase III trials reinforces the long-term efficacy profile of its MS treatment Gilenya. …
News

UCB plots new Vimpat submissions after positive monotherapy results

October 8, 2015 Research and Development EMA, European Medicines Agency, UCB, carbamazepine, epilepsy, lacosamide, phase III, vimpat

A Phase III non-inferiority study comparing UCB’s Vimpat with carbamazepine suggests the two drugs can be used as monotherapy treatments.  …
News
Genzyme

Genzyme’s Lemtrada shows five-year efficacy in extended trials

October 8, 2015 Research and Development Genzyme, Lemtrada, MS, RRMS, alemtuzumab, multiple sclerosis, relapsing-remitting multiple sclerosis

Sanofi’s subsidiary Genzyme has achieved positive data from an extension study of Lemtrada in patients with relapsing remitting multiple sclerosis …
News
Nobel Prize

Infectious diseases dominate Nobel Prize awards for medicine

October 8, 2015 Manufacturing and Production, Research and Development Nobel Prize, artemisinin, ivermectin, malaria, mectizan, river blindness

Pharma researchers have been awarded the 2015 Nobel Prize for their work on a river blindness treatment, along with work …
News
ms_symptoms

Multiple Sclerosis treatment will be a $20bn market by 2024

October 7, 2015 Research and Development multiple sclerosis

The value of the multiple sclerosis therapeutics market will rise slowly from $17.2 billion in 2014 to approximately $20 billion …
News
ms_early_intervention

Experts call for greater urgency in MS treatment

October 7, 2015 Research and Development multiple sclerosis

A therapeutic strategy in multiple sclerosis (MS) that aims to maximise lifelong brain health (neurological reserve) needs to be widely …
News
The Gateway to Local Adoption Series

Latest content

Kayentis and RWS partner to improve clinical trial data confidence

April 17, 2026

MHRA expands its pioneering AI Airlock programme with £3.6m funding boost

April 16, 2026

Ardena opens new US bioanalytical laboratory

April 15, 2026

Gesynta Pharma doses first patient in endometriosis phase 2 trial

April 14, 2026

Astellas Pharma’s new non-hormonal menopausal hot flush treatment Veoza can be used in the NHS, NICE says

April 13, 2026